Third Rock Ventures continues to systematically reduce its stake, with over $70M in sales in the past month. This persistent selling by a top-10 holder creates overhang and signals diminishing conviction. Monitor for further 144 filings and potential acceleration of sales ahead of any upcoming catalysts or lock-up expirations.
Price Chart
Executive Summary
Third Rock Ventures V, L.P., a 10% stockholder, filed a Form 144 on May 27, 2026, indicating intent to sell 18,572 shares of Rapport Therapeutics common stock, valued at approximately $742,880. The selling entity has been actively reducing its position, with four prior sales totaling ~836,136 shares in the past month, signaling continued distribution by a major insider.
Key Facts
- Third Rock Ventures V, L.P. (10% stockholder) filed Form 144 to sell 18,572 shares of RAPP common stock.
- Estimated value of proposed sale: $742,880.
- Selling entity has sold ~836,136 shares in four separate transactions between April 17 and May 11, 2026, totaling ~$70.6 million.
- Form 144 filed on May 27, 2026; proposed sale date listed as May 26, 2026.
- Total shares outstanding referenced: 47,826,929.
Financial Impact
Proposed sale of $742,880 represents ~0.04% of market cap; however, cumulative insider sales by Third Rock Ventures over the past month exceed $70 million.
Risk Factors
- Continued insider selling by a major stockholder may pressure the stock.
- Potential for additional unregistered sales if the entity files further 144 notices.
- Selling ahead of clinical data or earnings could indicate negative non-public information.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001974078-26-000199 |
| Document: 0001974078-26-000199-index.html | 0001974078-26-000199 |
| Document: 0001974078-26-000199.txt | 0001974078-26-000199 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | Insider Cluster | $26.00 | awaiting T+5 | — | $25.93 (−0.27%) |
Oct 22, 2026 4d ago | Insider Cluster | $27.33 | awaiting T+5 | — | $25.93 (−5.12%) |
Oct 21, 2026 4d ago | Insider Buy | $26.53 | awaiting T+5 | — | $25.93 (−2.26%) |
Oct 20, 2026 6d ago | 8-K | $29.37 | awaiting T+5 | — | $25.93 (−11.71%) |
Oct 6, 2026 19d ago | 144 | $30.86 $28.33 | ▲ +8.20% | ▲ +7.22% | $25.93 (+15.98%) |
Oct 1, 2026 24d ago | Insider Cluster | $32.17 $30.65 | ▼ −4.72% | ▼ −5.89% | $25.93 (−19.40%) |
Aug 26, 2026 8w ago | Insider Cluster | $50.83 $47.65 | ▼ −6.26% | ▼ −6.52% | $25.93 (−48.99%) |
Aug 5, 2026 11w ago | 8-K | $42.44 $47.73 | ▲ +12.46% | ▲ +12.11% | $25.93 (−38.90%) |
Jul 1, 2026 16w ago | Insider Cluster | $38.97 $41.75 | ▲ +7.13% | ▲ +5.77% | $25.93 (−33.46%) |
Jun 30, 2026 16w ago | 144 | $39.39 $39.72 | ▲ +0.84% | ▲ +0.58% | $25.93 (−34.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers